Atrium Therapeutics stock: Corventis trial reaches first dosing milestone
Published on 11/13/2026 at 00:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAtrium advances rare-heart-disease trial
- Atrium has dosed the first patient in the Phase 1/2 Corventis study of ATR 1072.
- The trial is designed to evaluate an RNA therapy for PRKAG2 syndrome, with initial proof-of-concept data expected in the second half of 2027.
Atrium Therapeutics said on October 27, 2026, that it had dosed the first patient in Corventis, a Phase 1/2 trial testing ATR 1072 in people with PRKAG2 syndrome. The company expects initial proof-of-concept data in the second half of 2027, according to the Atrium Therapeutics press release.
Trial targets genetic cardiomyopathy
Corventis is planned as an open-label, multicenter study with approximately 37 participants. Its primary endpoint is the incidence of treatment-emergent adverse events, while secondary and exploratory measures include PRKAG2 messenger RNA reduction, siRNA tissue concentrations, pharmacokinetics and changes in cardiac structure and function.
PRKAG2 syndrome is a rare inherited cardiomyopathy linked to mutations that can cause abnormal glycogen accumulation in heart muscle, conduction problems and arrhythmias. Atrium says there are no approved therapies addressing the underlying genetic driver of the disease.
Atrium builds targeted RNA medicines
Atrium Therapeutics is a U.S. biopharmaceutical company developing RNA therapeutics targeted to the heart. Its platform combines antibody or other targeted delivery ligands with oligonucleotides and is designed to deliver small interfering RNA to genetically driven cardiac diseases.
The company says its pipeline includes ATR 1072 for PRKAG2 syndrome, ATR 1086 for phospholamban cardiomyopathy and two undisclosed research programs. The release identifies Avidity Biosciences as the origin of the proprietary technology behind the platform.
Atrium Therapeutics at a glance
- Company: Atrium Therapeutics, Inc.
- ISIN: US05370A1088
- Ticker: RNA
- Exchange: Nasdaq
- Lead candidate: ATR 1072
- Trial: Corventis Phase 1/2
Broader market conditions remain relevant for clinical-stage biotechnology companies as investors weigh development milestones, funding needs and trial risk. See current S&P 500 market coverage.
For further company news and analysis, see More news and analyses on Atrium Therapeutics stock.
